JP7543247B2 - ヒトＴｉｍ－３に対するモノクローナル抗体 - Google Patents

ヒトＴｉｍ－３に対するモノクローナル抗体 Download PDF

Info

Publication number
JP7543247B2
JP7543247B2 JP2021502951A JP2021502951A JP7543247B2 JP 7543247 B2 JP7543247 B2 JP 7543247B2 JP 2021502951 A JP2021502951 A JP 2021502951A JP 2021502951 A JP2021502951 A JP 2021502951A JP 7543247 B2 JP7543247 B2 JP 7543247B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
binding fragment
tim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502951A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020041520A5 (enExample
JP2021534735A (ja
Inventor
ジャン、シンシン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of JP2021534735A publication Critical patent/JP2021534735A/ja
Publication of JPWO2020041520A5 publication Critical patent/JPWO2020041520A5/ja
Priority to JP2024083589A priority Critical patent/JP2024119853A/ja
Application granted granted Critical
Publication of JP7543247B2 publication Critical patent/JP7543247B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021502951A 2018-08-21 2019-08-21 ヒトＴｉｍ－３に対するモノクローナル抗体 Active JP7543247B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024083589A JP2024119853A (ja) 2018-08-21 2024-05-22 ヒトＴｉｍ－３に対するモノクローナル抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720234P 2018-08-21 2018-08-21
US62/720,234 2018-08-21
PCT/US2019/047573 WO2020041520A1 (en) 2018-08-21 2019-08-21 Monoclonal antibodies against human tim-3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024083589A Division JP2024119853A (ja) 2018-08-21 2024-05-22 ヒトＴｉｍ－３に対するモノクローナル抗体

Publications (3)

Publication Number Publication Date
JP2021534735A JP2021534735A (ja) 2021-12-16
JPWO2020041520A5 JPWO2020041520A5 (enExample) 2022-07-27
JP7543247B2 true JP7543247B2 (ja) 2024-09-02

Family

ID=69591459

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502951A Active JP7543247B2 (ja) 2018-08-21 2019-08-21 ヒトＴｉｍ－３に対するモノクローナル抗体
JP2024083589A Pending JP2024119853A (ja) 2018-08-21 2024-05-22 ヒトＴｉｍ－３に対するモノクローナル抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024083589A Pending JP2024119853A (ja) 2018-08-21 2024-05-22 ヒトＴｉｍ－３に対するモノクローナル抗体

Country Status (13)

Country Link
US (2) US12134645B2 (enExample)
EP (1) EP3841125A4 (enExample)
JP (2) JP7543247B2 (enExample)
KR (1) KR20210045999A (enExample)
CN (3) CN118667019A (enExample)
AU (1) AU2019325558A1 (enExample)
BR (1) BR112021003018A2 (enExample)
CA (1) CA3108879A1 (enExample)
IL (1) IL280757A (enExample)
MX (1) MX2020013428A (enExample)
NZ (1) NZ770219A (enExample)
SG (1) SG11202012148RA (enExample)
WO (1) WO2020041520A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024119853A (ja) * 2018-08-21 2024-09-03 アルバート アインシュタイン カレッジ オブ メディスン ヒトＴｉｍ－３に対するモノクローナル抗体

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021175191A1 (zh) * 2020-03-02 2021-09-10 信达生物制药(苏州)有限公司 抗tim-3抗体及其用途
WO2022223048A1 (en) * 2021-04-23 2022-10-27 Suzhou Neologics Bioscience Co. , Ltd. Tim-3-targetting antibodies and uses thereof
EP4494654A1 (en) 2022-03-14 2025-01-22 Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group Pharmaceutical composition of anti-tim-3 antibody and hypomethylating agent
WO2023174408A1 (zh) * 2022-03-18 2023-09-21 正大天晴药业集团南京顺欣制药有限公司 抗tim-3抗体与抗pd-l1抗体的药物组合
CN119053343A (zh) 2022-05-13 2024-11-29 正大天晴药业集团南京顺欣制药有限公司 抗tim-3抗体与抗pd-1抗体的药物组合
CN119789867A (zh) * 2022-09-06 2025-04-08 正大天晴药业集团股份有限公司 结合tim-3的抗体与结合pd-1的抗体的药物组合
CN120752053A (zh) * 2023-03-03 2025-10-03 正大天晴药业集团南京顺欣制药有限公司 含抗tim-3抗体的药物组合
WO2025056005A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 抗tim-3抗体的药物组合物及用途
WO2025056014A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 包含抗pd-1抗体和第二抗体的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017511687A (ja) 2014-01-31 2017-04-27 ノバルティス アーゲー Ｔｉｍ−３に対する抗体分子およびその使用
WO2017178493A1 (en) 2016-04-12 2017-10-19 Symphogen A/S Anti-tim-3 antibodies and compositions
WO2018036561A1 (en) 2016-08-26 2018-03-01 Beigene, Ltd. Anti-tim-3 antibodies and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2005033144A2 (en) 2003-10-03 2005-04-14 Brigham And Women's Hospital Tim-3 polypeptides
AU2004292180A1 (en) * 2003-11-13 2005-06-02 Genentech, Inc. Screening assays and methods of tumor treatment
KR101188117B1 (ko) 2005-03-31 2012-10-09 바이오메딕스 인코포레이티드 항ｃｄ20 모노클로날 항체
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2162471A1 (en) 2007-06-08 2010-03-17 Université de la Méditerranée Compositions and methods for treating pancreatic tumors
BR112012020101A2 (pt) 2010-02-11 2018-09-25 Alexion Pharma Inc método diagnósticos e terapêuticos usando anticorpos anti-cd200.
KR101846590B1 (ko) * 2010-06-11 2018-04-09 교와 핫꼬 기린 가부시키가이샤 항 ｔｉｍ-3 항체
US9321833B2 (en) 2011-04-04 2016-04-26 The Trustees Of Dartmouth College Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
US10053511B2 (en) * 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
MX2019005116A (es) * 2016-11-01 2019-11-12 Anaptysbio Inc Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
CN118667019A (zh) * 2018-08-21 2024-09-20 阿尔伯特爱因斯坦医学院 针对人tim-3的单克隆抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017511687A (ja) 2014-01-31 2017-04-27 ノバルティス アーゲー Ｔｉｍ−３に対する抗体分子およびその使用
WO2017178493A1 (en) 2016-04-12 2017-10-19 Symphogen A/S Anti-tim-3 antibodies and compositions
WO2018036561A1 (en) 2016-08-26 2018-03-01 Beigene, Ltd. Anti-tim-3 antibodies and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SABATOS-PEYTON, Catherine A. et al.，ONCOIMMUNOLOGY，2017年11月09日，Vol. 7, Issue 2, Article No. e1385690，DOI: 10.1080/2162402X.2017.1385690

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024119853A (ja) * 2018-08-21 2024-09-03 アルバート アインシュタイン カレッジ オブ メディスン ヒトＴｉｍ－３に対するモノクローナル抗体

Also Published As

Publication number Publication date
CN112566936A (zh) 2021-03-26
CA3108879A1 (en) 2020-02-27
US20210198357A1 (en) 2021-07-01
JP2021534735A (ja) 2021-12-16
SG11202012148RA (en) 2021-01-28
EP3841125A1 (en) 2021-06-30
IL280757A (en) 2021-04-29
JP2024119853A (ja) 2024-09-03
EP3841125A4 (en) 2022-05-11
CN118667020A (zh) 2024-09-20
US12134645B2 (en) 2024-11-05
AU2019325558A1 (en) 2020-12-17
BR112021003018A2 (pt) 2021-05-11
MX2020013428A (es) 2021-07-16
US20250034248A1 (en) 2025-01-30
WO2020041520A1 (en) 2020-02-27
CN112566936B (zh) 2024-07-12
CN118667019A (zh) 2024-09-20
KR20210045999A (ko) 2021-04-27
NZ770219A (en) 2025-11-28

Similar Documents

Publication Publication Date Title
JP7543247B2 (ja) ヒトＴｉｍ－３に対するモノクローナル抗体
CN112351997B (zh) 与cd19结合的重链抗体
AU2020291938B2 (en) Multispecific heavy chain antibodies binding to CD22 and CD3
EP3486257A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
KR20250093583A (ko) Cd22에 결합하는 중쇄 항체
EP4155318A1 (en) Bispecific antibody and use thereof
TW202233674A (zh) 用於調節δγ鏈介導之免疫的組成物及方法
JP2025084880A (ja) 共通軽鎖を含む抗体及びその使用
JP2022529340A (ja) ヒトｃｄ４７を標的とする抗体
US12145989B2 (en) Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof
CA3091307A1 (en) Csf1r binding agents
WO2019200255A1 (en) High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibody
RU2777336C1 (ru) Моноклональные антитела к tim-3 человека
HK40043135A (en) Monoclonal antibodies against human tim-3
HK40043135B (zh) 针对人tim-3的单克隆抗体
WO2022216672A1 (en) Anti-annexin a1 antibodies
TW202448953A (zh) 用於腫瘤及轉移之治療的基於沉默抗體的抗met建構物
US20210163578A1 (en) High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibody
KR20250110219A (ko) 표피 성장 인자 수용체 변이체 iii 항체
JP2023551907A (ja) 腫瘍関連抗原及びｃｄ３結合タンパク質、関連する組成物、及び方法
HK40036534A (en) Heavy chain antibodies binding to cd22
HK40003752A (en) Humanized and chimeric monoclonal antibodies to cd81

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230926

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240522

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240821

R150 Certificate of patent or registration of utility model

Ref document number: 7543247

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150